Times:

03:17 Asgard Therapeutics

32:43 Waiv

This week, we talk to a company in Lund, Asgard Therapeutics, and its co-founder and CEO Cristiana Pires, about in vivo direct cell reprogramming for cancer immunotherapy, and we chat about clinical diagnostics with Meriem Sefta, CEO of Waiv.

Asgard Therapeutics

Asgard Therapeutics is a biotech pioneering in vivo direct cell reprogramming for cancer immunotherapy.

Asgard is using an innovative approach to force tumour cells to present their antigens to the immune system, thereby triggering personalised anti-tumour immune responses.

The team presented advanced preclinical data on lead asset AT-108 at ASGCT earlier this year, showing that, when used as a monotherapy,  ...